Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease

• ClinicalTrials.gov Identifier: NCT02907567
• Recruitment Status: Completed
• First Posted: September 20, 2016
• Last Update Posted: July 26, 2018
• Sponsor: Cognition Therapeutics
• Information provided by (Responsible Party): Cognition Therapeutics

Study Description

Brief Summary:

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the safety and tolerability of oral CT1812, administered for 28 days. This trial may include up to 8 qualified investigator sites in Australia.

Condition or disease	Intervention/treatment	Phase
Alzheimer's Disease	Drug: CT1812; Drug: Placebo	Phase 1; Phase 2

Detailed Description:

Screening procedures will occur up to 42 days. Eligible subjects will randomized at the clinic on Day 1 and receive the first dose of study drug. Dosing for 28 days thereafter off-site and a total of 5 clinic visits over the treatment period for safety and lab assessments. Then a 7 day post-treatment completion follow-up visit (Day 35) and End of Study for last safety assessments (Day 49).

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 19 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease
• Actual Study Start Date: September 2016
• Actual Primary Completion Date: August 24, 2017
• Actual Study Completion Date: September 2017

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Active Treatment-Low; 6 subjects randomized to 280 mg (Low) CT1812	Drug: CT1812; Active study drug; Other Name: Study Drug
Active Comparator: Active Treatment-High; 6 subjects randomized to 560 mg (High) CT1812	Drug: CT1812; Active study drug; Other Name: Study Drug
Placebo Comparator: Placebo; 4 subjects randomized to matching placebo of CT1812	Drug: Placebo; non-active study drug; Other Name: Matching placebo

Outcome Measures

Primary Outcome Measures :

1. Incidence and review of Treatment Emergent Adverse Events [ Time Frame: Up to 30 days ]
   Treatment Emergent Adverse Events will be assessed by reviewing: Physical Exams; monitoring of vital signs, ECGs, and clinical and laboratory assessments

Eligibility Criteria

• Ages Eligible for Study: 50 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Willing and able to provide written informed consent prior to initiation of any study-related procedures. For subjects unable to provide written consent, consent will be provided by the Person Responsible per local regulations.
2. Men and women, 50-80 years in age inclusively with a diagnosis of mild to moderate Alzheimer's disease according to the 2011 NIA-AA. Women must be neither pregnant nor nursing, and are either surgically sterile, postmenopausal or premenopausal using an acceptable method of contraception.
3. Previous decline in cognition for more than six months.
4. Neuroimaging (MRI) obtained within the previous 6 months or during screening, consistent with the clinical diagnosis of Alzheimer's disease.
5. MMSE 18-26 inclusive.
6. No active depression and a Geriatric Depression Score (GDS) of < 6.
7. Modified Hachinski Ischemia score ≤ 4.
8. Formal education of eight or more years.
9. Living at home or in a community setting (assisted living) without continuous nursing care. Each subject must have a reliable caregiver who sees them at least 3 times weekly, can oversee the administration of study drug, and is willing and able to participate in all clinic visits and some study procedures. Responsible caregiver must provide written informed consent to participate.
10. Concurrent use of acetylcholinesterase inhibitors or memantine must be stable for 90 days prior to screening and not expected to change.

Exclusion Criteria:

1. History of or screening brain MRI scan indicative of significant abnormality, including, but not limited to, prior hemorrhage or infarct > 1 cm3, >3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g. abscess or brain tumor such as meningioma).

2. Clinical or laboratory findings consistent with:

   1. Other primary degenerative dementia,
   2. Other neurodegenerative condition
   3. Seizure disorder
   4. Other infectious, metabolic or systemic diseases affecting the central nervous system
3. A current DSM-V diagnosis of active major depression, schizophrenia or bipolar disorder.
4. Clinically significant, advanced or unstable disease that may interfere with outcome measures, and which may bias the assessment of the clinical or mental status of the patient or put the patient at special risk

Contacts and Locations

Locations

Australia, Queensland

Dr. Phillip Morris

Southport, Queensland, Australia

Australia, Victoria

Austin Health

Ivanhoe, Victoria, Australia, 3079

Epworth Hospital

Melbourne, Victoria, Australia, 3121

The Royal Melbourne Hospital Hospital

Parkville, Victoria, Australia, 3050

Sponsors and Collaborators

Cognition Therapeutics

Investigators

• Principal Investigator: Michael Woodward, MD; Austin Health

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Waybright L, Look G, Rishton G, Safferstein H, Hamby ME, Williams C, Sadlek K, Edwards HM, Davis CS, Grundman M, Schneider LS, DeKosky ST, Chelsky D, Pike I, Henstridge C, Blennow K, Zetterberg H, LeVine H 3rd, Spires-Jones TL, Cirrito JR, Catalano SM. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. Alzheimers Dement. 2021 Aug;17(8):1365-1382. doi: 10.1002/alz.12302. Epub 2021 Feb 8.

• Responsible Party: Cognition Therapeutics
• ClinicalTrials.gov Identifier: NCT02907567
• Other Study ID Numbers: COG0102
• First Posted: September 20, 2016
• Last Update Posted: July 26, 2018
• Last Verified: July 2018

Additional relevant MeSH terms:

Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders